Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mi-Ae Lyu

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Molecular Cancer Therapeutics|August 12, 2005
The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1Mi-Ae Lyu, Michael G Rosenblum
Biochemical Pharmacology|December 18, 2007
The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell linesMi-Ae Lyu, Razelle Kurzrock, Michael G Rosenblum
Methods in Enzymology|January 3, 2012
Cell-targeting fusion constructs containing recombinant geloninMi-Ae Lyu, Yu Joshua Cao, Khalid A Mohamedali, et al.
Blood|November 23, 2006
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cellsRamadevi Nimmanapalli, Mi-Ae Lyu, Min Du, et al.
Frontiers in Transplantation|December 26, 2024
Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomesKe Zeng, Hongbing Ma, Meixian Huang, et al.
Iscience|September 24, 2024
CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammationMeixian Huang, Zeng Ke, Mi-Ae Lyu, et al.
Molecular Imaging and Biology|August 6, 2010
Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphomaXiaoxia Wen, Mi-Ae Lyu, Rui Zhang, et al.
Frontiers in Immunology|February 20, 2025
Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLEMi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, et al.
Molecular Cancer Therapeutics|February 3, 2007
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMAMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Cancer Letters|March 6, 2012
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxinMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Molecular Cancer Therapeutics|August 12, 2005
The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1Mi-Ae Lyu, Michael G Rosenblum
Biochemical Pharmacology|December 18, 2007
The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell linesMi-Ae Lyu, Razelle Kurzrock, Michael G Rosenblum
Methods in Enzymology|January 3, 2012
Cell-targeting fusion constructs containing recombinant geloninMi-Ae Lyu, Yu Joshua Cao, Khalid A Mohamedali, et al.
Blood|November 23, 2006
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cellsRamadevi Nimmanapalli, Mi-Ae Lyu, Min Du, et al.
Frontiers in Transplantation|December 26, 2024
Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomesKe Zeng, Hongbing Ma, Meixian Huang, et al.
Iscience|September 24, 2024
CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammationMeixian Huang, Zeng Ke, Mi-Ae Lyu, et al.
Molecular Imaging and Biology|August 6, 2010
Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphomaXiaoxia Wen, Mi-Ae Lyu, Rui Zhang, et al.
Frontiers in Immunology|February 20, 2025
Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLEMi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, et al.
Molecular Cancer Therapeutics|February 3, 2007
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMAMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Cancer Letters|March 6, 2012
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxinMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Pageof 2